Colorectal cancer

This study tests a vaccine that helps the body's immune system recognize and attack advanced colon polyps, which can turn into cancer. About 110 people who have had these polyps removed will receive either the vaccine or a placebo. The goal is to see if the vaccine boosts immune …

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This expanded access program provides continued treatment with CA102N plus lonsurf to a single patient with advanced or metastatic colorectal cancer. The patient had already completed at least 12 cycles of the same combination in an earlier clinical study. Expanded access allows …

Researchers are testing whether adding an experimental drug called CA102N to the chemotherapy TAS-102 helps control metastatic colorectal cancer better than adding bevacizumab to TAS-102. The trial enrolls about 100 adults whose cancer has grown after standard chemotherapy. Parti…

This early-stage trial is testing an experimental oral drug called RGT-61159 in about 105 people with two types of cancer that have come back or stopped responding to treatment: adenoid cystic carcinoma (a rare salivary gland cancer) and colorectal cancer. The main goals are to c…

Researchers are testing whether a blood test that detects tiny amounts of tumor DNA can guide chemotherapy after surgery for early colon cancer. The trial compares two chemotherapy regimens: an intensive one called FOLFOXIRI and a standard one called CAPOX. They want to see if th…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This trial is testing whether giving the immunotherapy drug pembrolizumab before surgery can improve outcomes for people with high-risk stage 2 or stage 3 colorectal cancer that has a specific genetic feature called mismatch repair deficiency. About 88 participants will receive p…

This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…

This phase 2 trial is testing whether combining an experimental drug called S-531011 with a precise radiation technique known as RadScopal can help control metastatic colorectal cancer that has not responded to prior treatments. The study enrolls about 30 adults with advanced dis…

This early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…

This study tests a device called ColoSeal ICD that is placed inside the colon after surgery to divert stool away from the surgical connection. The goal is to see if it is safe and feasible in 90 adults with rectal or rectosigmoid cancer. The device stays in place for about 10 day…

This Phase 2 study tests whether adding leronlimab to standard chemotherapy and a targeted drug can shrink tumors or improve survival in people with a specific type of advanced colorectal cancer (MSS mCRC) that has not responded to prior treatments. About 66 adults will receive o…

This study is for people with a certain genetic type of advanced colorectal cancer (BRAF V600E) who previously benefited from a specific drug combination (encorafenib plus cetuximab). Researchers want to see if giving these drugs again, guided by a blood test that looks for cance…

This phase III trial compares two first-line treatments for people with a specific genetic subtype of metastatic colorectal cancer (dMMR/MSI-H). One group receives the immunotherapy drug atezolizumab alone, while the other gets atezolizumab combined with chemotherapy (FOLFOX) and…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This early-stage trial tests an experimental drug called ONO-4578, both on its own and together with another experimental drug, ONO-4538, in people with advanced or metastatic solid tumors. The study also includes separate groups for people with gastric cancer or colorectal cance…

This early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…

This trial tests whether adding dihydroartemisinin, a malaria drug, to a standard chemotherapy plus immunotherapy combo can shrink or eliminate colorectal tumors in people whose cancer has not spread widely or has returned after first-line treatment. The goal is to make surgery m…

This phase 1 trial tests an experimental cell therapy called IX001 TCR-T in adults with advanced pancreatic or colorectal cancer that has not responded to at least two standard treatments. The therapy uses a patient's own immune cells, engineered to recognize cancer cells with KR…

This early-phase trial is testing a combination of chemotherapy (FOLFOX), an anti-angiogenic drug (bevacizumab), and two immunotherapies (botensilimab and balstilimab) in 20 patients with MSS metastatic colorectal cancer, a type that usually doesn't respond to immunotherapy. The …

This study tests a new oral drug called IPN01194 in 36 adults with advanced solid tumours (melanoma, colorectal, pancreatic, or head and neck cancer) that have not responded to standard treatments. The goal is to find the right dose and check if it is safe, while also looking for…

This early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …

This study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-s…

This study tests a combination of three drugs (botensilimab, balstilimab, and regorafenib) in people with a type of advanced colorectal cancer that is hard to treat (MSS type) and has worsened after standard chemotherapy. The goal is to see if this mix can shrink tumors or slow t…

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This study tests whether early, personalized nutritional support and a simple home exercise program can prevent weight loss and improve quality of life in 200 adults with lung, colorectal, ovarian, or pancreatic cancer starting palliative chemotherapy. Participants receive guidan…

This study tests a combination of three drugs—bintrafusp alfa, PDS01ADC, and entinostat—in adults with advanced HPV-related cancers (like cervical, anal, or throat cancer) or certain colon cancers that haven't responded to standard treatment. The goal is to find a safe dose and s…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This early-stage trial tests an experimental drug called DM001 in people with advanced solid tumors, including breast cancer, non-small cell lung cancer, and other solid cancers that have progressed on standard treatment. The main goals are to find a safe dose, identify side effe…

This study tests an experimental vaccine (RO7198457) in people with stage II or III colorectal cancer who have signs of remaining cancer DNA in their blood after surgery. The goal is to see if the vaccine can prevent the cancer from returning better than simply watching and waiti…

This early-phase study tests a new drug, GDC-6036, in people with advanced cancers (like lung or colorectal) that have a specific KRAS G12C mutation. The goal is to check safety and find the right dose, both when used alone and with other cancer drugs. About 498 participants will…

This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-stage study tests an experimental drug called INCB186748 in people with advanced or spreading solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety and find the right dose. About 30 adults whose cancer has not …

This phase 2 trial is testing whether a combination of four drugs—BMS-986340, nivolumab, trifluridine/tipiracil, and bevacizumab—can help control advanced colorectal cancer that has not responded to standard treatments. The study is for people with a specific type called microsat…

This study tests whether a drug called QBECO, given as a self-injection before and after liver surgery, can lower the chance of colorectal cancer coming back or spreading. About 115 adults with colorectal cancer that has spread to the liver will take part. They will inject the dr…

This early-phase trial tests whether adding the CIMAvax-EGF vaccine to standard chemotherapy and targeted drugs can trigger an immune response against metastatic colorectal cancer. Only 2 participants with a specific gene type (RAS/BRAF wild-type) were enrolled. The main goal is …

This trial tests a new drug called BAY 1895344 (elimusertib) combined with standard chemotherapy (FOLFIRI) in people with advanced or metastatic stomach or colorectal cancer. The goal is to find the safest dose and see if the combination can shrink tumors. Participants receive th…

This trial asks whether adding maximal tumor debulking—removing or destroying as many metastases as possible through surgery, heat ablation, chemo-embolization, or targeted radiation—to standard chemotherapy improves overall survival in people with colorectal cancer that has spre…

This study tests a new drug called PF-07220060 in people with advanced solid tumors, including breast, prostate, lung, and liposarcoma cancers. The drug is given alone or with hormone therapies to see if it is safe and works. About 362 participants will take part to find the best…

This phase 3 trial compares two immunotherapy drugs (nivolumab alone or with ipilimumab) against standard chemotherapy in 839 people with a specific genetic type of advanced colorectal cancer (MSI-H/dMMR). The goal is to see if the immunotherapies work better at stopping cancer g…

This long-term extension study offers continued access to several cancer drugs—including cabozantinib, atezolizumab, and nivolumab—for up to 5,000 patients who benefited from them in earlier Exelixis-sponsored trials. The study focuses on monitoring safety and ongoing clinical be…

This study offers continued access to the cancer drug ruxolitinib (sometimes combined with other therapies) for people with pancreatic, colorectal, breast, or lung cancer who were already benefiting and stable in a prior Incyte-sponsored trial. Only 10 participants are enrolled, …

This early-phase trial is testing whether adding a new targeted drug called adagrasib to two existing cancer drugs (cetuximab and irinotecan) is safe and tolerable for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. The study will enrol…

This early-stage trial tests a personalized treatment for people with metastatic solid cancers that have KRAS mutations. Doctors take a patient's own white blood cells, genetically modify them to recognize and attack KRAS-mutated cancer cells, and return them to the patient along…

This study tests a new drug, APL-5125, in adults with advanced solid tumors like colorectal, pancreatic, and ovarian cancer. The goal is to see if the drug is safe and can shrink or control tumors. About 100 participants will receive the drug in two phases to find the best dose a…

This phase 2 trial is testing whether adding PET-guided radiation and an immunotherapy drug called cadonilimab to standard chemotherapy can shrink tumors better than chemotherapy alone in people with colorectal cancer that has spread to the lining of the abdomen. The study will e…

This study tests whether two drugs, fruquintinib and tislelizumab, can control leftover cancer cells in people with colorectal cancer who have completed chemotherapy but still show signs of minimal residual disease (MRD) on a blood test. About 20 adults with stable disease will r…

This early-phase study tests an experimental drug called M9140 in 12 Chinese patients with advanced colorectal cancer that has not responded to standard treatments. The drug works like a guided missile, delivering chemotherapy directly to cancer cells that carry a specific marker…

This study tests a new drug called SHR-8068 combined with other cancer treatments for people with colorectal cancer. The goal is to see if the combination is safe and helps shrink tumors or slow cancer growth. About 200 adults aged 18 to 75 will take part, and they must provide t…

This study tests whether adding new cancer drugs to standard chemotherapy and bevacizumab can better control metastatic microsatellite-stable colorectal cancer. About 61 adults with this advanced cancer will receive different treatment combinations. The goal is to find safer, mor…

This trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…

This early-phase trial tests whether giving two standard chemotherapy drugs (5FU and oxaliplatin) directly into the abdominal cavity is safe for people with colorectal cancer that has spread only to the peritoneal lining. About 24 adults will receive the drugs through a catheter …

This phase II trial is testing whether a blood test that looks for tumor DNA (ctDNA) can help doctors choose between two standard drugs—regorafenib or TAS-102—for people with advanced colorectal cancer that has stopped responding to other treatments. The study will enroll 100 par…

This early-phase trial is testing a new drug called enzelkitug, alone or with standard immunotherapies, in people with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. A…

This study explores whether regular aerobic exercise, specifically walking about 300 minutes per week, can change certain biomarkers in the blood that are linked to cancer risk. Participants are adults who have completed all cancer therapy and have either clonal hematopoiesis (a …

This early-phase trial tests an experimental antibody called GEN1042, given alone or with the cancer drug pembrolizumab (and sometimes chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check …

This early-phase trial tests a new combination therapy for people with colorectal cancer who have minimal residual disease (MRD) — tiny amounts of cancer left after treatment. The approach uses specially engineered immune cells from cord blood (TROP2-CAR-NK cells) plus a targeted…

This trial is testing whether combining two standard drugs—fruquintinib and TAS-102—can help people with metastatic colorectal cancer that has stopped responding to at least two prior chemotherapy regimens. The study will measure how long patients live without the disease getting…

This early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…

This study tests whether adding two targeted drugs (encorafenib and cetuximab) to standard immunotherapy (pembrolizumab) works better than immunotherapy alone for people with a specific genetic type of advanced colorectal cancer. About 107 participants with untreated, metastatic …

This phase 2 trial tests whether combining two immunotherapy drugs (durvalumab and tremelimumab) with or without radiation therapy can shrink tumors in people with metastatic colorectal or non-small cell lung cancer. About 110 participants will receive the drugs alone or with hig…

This study tests a new drug called M9140 in people with advanced colorectal cancer that has not responded to standard treatments. The drug works by targeting a protein on cancer cells to deliver a chemotherapy-like agent directly to the tumor. The trial has two parts: first findi…

This early-phase trial is testing a vaccine that targets mutated KRAS proteins, combined with two immunotherapy drugs (nivolumab and ipilimumab), in 27 patients with pancreatic or colorectal cancer that has been surgically removed. The goal is to see if the vaccine can safely boo…

This study looks at people with advanced colorectal cancer whose tumor tissue shows no RAS/BRAF mutation, but a liquid biopsy (blood test) finds a RAS mutation. It compares two standard drug combos (FOLFIRI plus either cetuximab or bevacizumab) to see which works better at stoppi…

This study tests whether adding two experimental drugs (LBL-007 and tislelizumab) to standard maintenance therapy can help control advanced colorectal cancer that has not spread widely. About 113 adults with unresectable or metastatic colorectal cancer will receive either the new…

This phase 3 trial tests whether a new targeted drug (MRTX849) combined with cetuximab works better than standard chemotherapy for people with advanced colorectal cancer that has a specific KRAS G12C mutation. About 461 participants whose cancer worsened after first-line treatmen…

This early-phase trial tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ziv-aflibercept (which cuts off blood supply to tumors)—in people with advanced solid tumors like melanoma, colorectal, ovarian, and kidney cance…

This early-stage study tests a new experimental drug called PF-07934040, taken as a pill, for people with advanced solid tumors that have a KRAS gene mutation. The trial includes patients with non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Researchers will …

This study tests whether a structured endurance exercise program, like walking or cycling, after finishing chemotherapy can help prevent colorectal cancer from returning. About 92 patients who have completed adjuvant chemotherapy will be randomly assigned to either an exercise pr…

This Phase 2 trial is testing whether linaclotide, a drug currently used for constipation, can slow or prevent colorectal cancer growth. About 150 people with colorectal polyps or early-stage cancer will take the drug or a placebo before surgery. Researchers will measure changes …

This study tests a drug called tisotumab vedotin, alone or with other cancer medicines, in people with advanced colorectal, lung, pancreatic, or head and neck cancers that have stopped responding to standard treatments. About 350 participants receive different dosing schedules to…

This trial tests an experimental drug called ST316, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study focuses on tumors that may have abnormalities in a cell signaling pathway called WNT/β-catenin. The…

This study tests a new drug, SX-682, alone and with the immunotherapy nivolumab, in people with a specific type of advanced colorectal cancer that has spread or cannot be removed. The cancer must have a RAS mutation and be microsatellite stable (MSS), which often makes it harder …

This early-stage trial is testing a new oral drug called LY4066434, which blocks several types of KRAS proteins that drive cancer growth. The study includes up to 750 people with advanced pancreatic, lung, colorectal, or other solid tumors that have specific KRAS mutations. The d…

This phase 3 trial tests whether a new drug combination (XL092 plus atezolizumab) works better than the current standard drug regorafenib for people with advanced colorectal cancer that has not responded to other treatments. About 900 participants will receive either the new comb…

This study tests two drugs, panitumumab and trametinib, in people with stage IV colorectal cancer that no longer responds to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth. About 59 participants will receive either panitumumab alone…

This phase 3 trial tests whether adding bevacizumab (a drug that starves tumors by blocking new blood vessels) to standard maintenance chemotherapy helps people with metastatic colorectal cancer stay progression-free longer. About 400 adults whose disease is controlled after 4–6 …

This phase 2 trial studies whether combining chemotherapy with surgery to remove lung tumors works better than either treatment alone for patients with colorectal cancer that has spread only to the lungs. About 40 participants will be grouped by risk level to see if the combinati…

This study tests a drug called TPST-1495 in people with endometrial or colorectal cancer who are scheduled for surgery. The drug aims to help the immune system fight cancer by blocking certain signals. Researchers will check blood and tumor samples before and after treatment to s…

This early-phase study tests whether giving healthy donor NK cells along with two medicines (vactosertib and IL-2) is safe and helps the cells stay active in people with advanced colorectal, stomach, esophageal, or blood cancers. The NK cells are meant to attack cancer, but the b…

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This study tests a new oral drug called LNS8801, alone or combined with the immunotherapy pembrolizumab (Keytruda), in up to 200 adults with advanced solid tumors that have spread. The goal is to find a safe dose and see if the drug shrinks tumors. It is an early-stage trial, so …

This phase 1 trial tests a new method of delivering chemotherapy for people with cancers that have spread to the lining of the abdomen (peritoneal carcinomatosis) from gastrointestinal cancers like colorectal, stomach, or pancreatic cancer. The drug, nanoliposomal irinotecan (Oni…

This trial investigates whether combining two drugs—galunisertib and capecitabine—can help people with advanced colorectal cancer that has spread to the lining of the abdomen (peritoneal metastases) and no longer responds to standard chemotherapy. The study has two parts: first, …

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This study tests a therapy called CEA CAR-T, which uses a patient's own immune cells modified to recognize and attack cancer cells that carry a protein called CEA. It is for adults aged 18-75 with advanced or recurrent solid tumors (such as lung, colorectal, liver, pancreatic, ga…

This phase 2 trial tests whether a modified virus (VV1) combined with the immunotherapy drug cemiplimab can shrink tumors in people with colorectal cancer, head and neck squamous cell carcinoma, or melanoma that has stopped responding to checkpoint inhibitor treatment. The virus …

This phase II trial tests whether adding the immunotherapy drug nivolumab to the standard two-drug regimen (encorafenib and cetuximab) works better at shrinking tumors in people with a specific type of advanced colorectal cancer (BRAF-mutant, microsatellite stable). About 86 part…

This clinical trial is testing whether combining two drugs—capecitabine (a chemotherapy pill) and lenvatinib (a targeted therapy)—can shrink tumors in people with advanced colorectal cancer that has stopped responding to standard treatments. The study enrolls adults aged 19 and o…

This early-stage trial tests a new drug called OKI-219 in people with advanced solid tumors or breast cancer that have a specific PI3K gene mutation. The drug is designed to block the mutant protein and slow cancer growth. Up to 200 participants will receive OKI-219 alone or comb…

This Phase 2 trial tests a combination of pembrolizumab (Keytruda) and quavonlimab against other drug combos in 302 people with stage IV colorectal cancer that has a specific genetic feature (MSI-H or dMMR). The goal is to see if the new combo shrinks tumors better and for longer…

This study tests a combination of two oral drugs, D-1553 and IN10018, in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the best dose and see if the combination can shrink tumors or slow their growth. About 140 adults w…

This study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…

This early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…

This study tests whether following the Norwegian dietary guidelines—including healthy foods, cooking classes, and physical activity—can improve survival and reduce cancer recurrence in 503 people who had colorectal cancer. Participants are guided by nutritionists and given food d…

This trial tests a new drug called Cadonilimab in 28 people with advanced colorectal cancer that has not responded to standard immunotherapy. The drug is a bispecific antibody that targets two immune checkpoints (PD-1 and CTLA-4) to potentially reactivate the immune system agains…

This trial tests an experimental drug called TRK-950 in combination with several standard anti-cancer treatments for people with advanced solid tumors, including colorectal, bladder, ovarian, and other cancers. The main goal is to find safe doses and understand side effects. Part…

This trial investigates whether using a special dye called indocyanine green (ICG) during surgery helps improve outcomes for people with stage III colorectal cancer. The dye makes lymph nodes and cancer tissue glow under a special camera, helping surgeons see and remove more of t…

This study tests whether adding hydroxychloroquine (a malaria drug) to standard chemotherapy can help people with metastatic colorectal cancer that has a specific genetic marker. About 155 participants will be screened, and up to 31 with the marker will receive the drug combinati…

This phase 2 trial is testing a combination of three drugs—ATRA (a vitamin A derivative), bevacizumab (a blood vessel growth blocker), and atezolizumab (an immunotherapy)—in 22 people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see i…

This early-stage trial is testing a personalized peptide vaccine for people with advanced pancreatic or colorectal cancer that has spread. The vaccine is made from each patient's own tumor cells and blood, aiming to train the immune system to attack the cancer. The study will che…

This study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This study tests two drugs—regorafenib (a chemotherapy pill) and pembrolizumab (an immunotherapy)—in people with metastatic colorectal cancer who have already tried several other treatments. The goal is to see if the combination is safe and can slow tumor growth. About 73 partici…

This phase 2 trial tests whether adding an experimental drug called onvansertib to standard chemotherapy and bevacizumab can shrink tumors better than chemo alone in people with advanced colorectal cancer that has a KRAS or NRAS mutation. About 110 participants who have not had p…

This study tests a new drug called JDQ443, which targets a specific cancer-driving mutation (KRAS G12C), in combination with other drugs (trametinib, ribociclib, or cetuximab). The trial enrolls about 74 people with advanced solid tumors (like lung or colorectal cancer) that have…

This phase 3 trial tests whether taking a low-dose aspirin (100 mg) daily for three years can prevent colon cancer from coming back after surgery. It includes 264 people with stage II or III colon cancer who have a specific mutation in the PI3K gene. Participants are randomly ass…

This pilot trial tests whether giving fecal microbiota transplants (FMT) along with re-introducing anti-PD-1 immunotherapy (pembrolizumab or nivolumab) can help control metastatic colorectal cancer in patients who previously did not respond to immunotherapy alone. The study enrol…

This study tests whether a combination of two targeted drugs (encorafenib and cetuximab), given alone or with chemotherapy, works better than standard chemotherapy for people with a specific genetic form of advanced colorectal cancer (BRAF V600E mutation) that has spread and hasn…

This Phase II trial tests whether giving anti-EGFR drugs (panitumumab or cetuximab) early in treatment can help patients with left-sided metastatic colorectal cancer respond again to these drugs later. About 34 participants will receive alternating cycles of targeted therapy and …

This study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with radiation therapy can control or shrink tumors in people with colorectal or pancreatic cancer that has specific genetic features (MSS or MSI-high). About 84 adults with advanced disease are…

This study is testing whether a short-term, low-calorie diet called a fasting mimicking diet (FMD) can help patients recover better after surgery for colorectal cancer. The diet is given in cycles after the operation and is designed to be easier to follow than complete fasting. R…

This study tests a combination of two targeted drugs (encorafenib and cetuximab) plus an immunotherapy (nivolumab) in people with a specific type of advanced colorectal cancer (BRAF V600E mutation) that is stable (MSS) and has spread or can't be removed by surgery. The goal is to…

This study tests a combination of three drugs (cetuximab, LY3214996, and abemaciclib) in people with advanced colorectal cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors and improve survival. About 46 adult…

This early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…

This early-phase trial tests an experimental drug called HFB200603, either alone or with the immunotherapy tislelizumab, in 83 adults with advanced solid tumors (kidney, lung, melanoma, stomach, or colon cancer). The main goal is to find a safe dose and check for side effects. Re…

This phase 2 study tests a personalized immune cell therapy called tumor-infiltrating lymphocytes (TIL) in 20 people with advanced solid cancers (like stomach, colon, or pancreatic cancer) that have not responded to standard treatments. Patients first receive chemotherapy to prep…

This study looks at how well a new robotic surgical system works for removing colon or rectal tumors. About 60 adults who need surgery for benign or malignant colorectal conditions will take part. The goal is to see if the system is safe and can complete the surgery without switc…

This phase II trial tests whether delivering chemotherapy directly into the liver (hepatic arterial infusion) along with standard IV chemo can shrink inoperable liver tumors from colorectal cancer enough to allow surgical removal. The study involves 64 participants whose cancer h…

This study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …

This study tests whether giving two immunotherapy drugs (IBI310 and sintilimab) before surgery can eliminate or shrink tumors in people with a specific genetic type of colon cancer (MSI-H/dMMR). About 453 adults with stage IIB or III colon cancer that can be surgically removed wi…

This study aimed to test a new treatment called CAR-T cell therapy for people with advanced colorectal cancer. The therapy uses specially modified immune cells to target two proteins on cancer cells. However, the study was withdrawn before any participants were enrolled, so no re…

This phase 3 trial tests two different doses of an investigational drug called telisotuzumab adizutecan in about 74 adults with metastatic colorectal cancer that has stopped responding to standard treatments and whose tumors have a specific protein (c-Met). The drug is given by I…

This study tests a more intense chemotherapy regimen (mFOLFOXIRI) plus the drug bevacizumab against a standard regimen (mFOLFOX-6) plus bevacizumab as a first treatment for people with advanced colorectal cancer that cannot be removed by surgery. The trial includes 528 participan…

This phase 2 pilot study is testing whether giving two immunotherapy drugs, botensilimab and balstilimab, before surgery can shrink tumors in people with colorectal cancer. The trial includes 26 participants across three groups, with some receiving more doses and one group having…

This study compares the immunotherapy drug pembrolizumab with standard chemotherapy in about 100 Chinese patients whose advanced colorectal cancer has a specific genetic feature (MSI-H or dMMR). The goal is to see if pembrolizumab can slow cancer growth or improve survival better…

This study is testing whether a combination of three drugs—trifluridine/tipiracil, capecitabine, and bevacizumab—can safely control metastatic colorectal cancer in people who are not healthy enough for standard intensive chemotherapy. The first part finds the best dose, and the s…

This study tests a new immunotherapy drug, HX008, against standard chemotherapy for people with a specific type of advanced colorectal cancer (MSI-H/dMMR). The goal is to see if HX008 can delay cancer growth better than chemotherapy. About 190 adults with this genetic marker will…

This early-phase study tests a new drug called RMC-6291 in adults with advanced cancers (lung, colon, pancreatic) that have a specific KRAS G12C mutation. The goal is to find the safest dose and see how well the drug works. About 222 participants will receive the drug by mouth, a…

This study tests two drug combinations for people with advanced colorectal cancer that has a specific genetic change called KRAS G12C. In one group, patients who haven't had treatment yet will receive the drugs IBI351 and cetuximab β plus chemotherapy (FOLFIRI). In another group,…

This early-phase study tests an investigational drug called telisotuzumab adizutecan in about 30 Chinese adults with advanced colorectal cancer that cannot be removed by surgery. The main goals are to check safety and how the drug moves through the body. Participants receive diff…

This phase 2 trial is testing whether adding the drug sodium valproate (commonly used for seizures and mood disorders) to standard targeted therapy (panitumumab or cetuximab) can help control metastatic colorectal cancer longer. The study involves 38 adults with a specific geneti…

This study tests the safety and effectiveness of combining the experimental drug AVUTOMETINIB (VS-6766) with cetuximab in people with advanced colorectal cancer that has a KRAS mutation. It is for those whose cancer worsened after prior treatments or who cannot tolerate them. The…

This trial is for people with colorectal cancer that has spread to a few spots in the body but cannot be fully removed by surgery alone. After 3-4 months of standard chemotherapy, participants either continue chemotherapy alone or also receive local ablative therapy—such as surge…

This early-phase study tests a new treatment called WD-01, which uses a patient's own immune cells modified to target a protein (GCC) found on colorectal cancer cells. The goal is to see if it is safe and can shrink tumors in people with metastatic colorectal cancer who have alre…

This early-phase trial tests a new universal CAR-T cell therapy (REVO-UWD-01) in 30 adults with metastatic colorectal cancer that has spread. The treatment targets a protein called GCC found on cancer cells. The main goals are to find the safest dose and check for side effects, w…

This study compares two standard treatments for lung tumors: microwave ablation, which uses heat to kill cancer cells, and surgical wedge resection, which removes a small piece of lung. Researchers want to see which method works better and is safer for patients with non-small cel…

This trial tests a nurse-led health program for women aged 45 to 64 in Hong Kong. The program uses a 5-step approach (ask, advice, assess, assist, arrange) to help women manage conditions like high blood pressure, anxiety, and menopause symptoms. Researchers will compare the prog…

This study tests a temporary device called Colovac that is placed inside the bowel after colon cancer surgery to protect the surgical connection. The goal is to see if it can help patients avoid needing a temporary stoma bag. About 108 adults with colon cancer will take part, and…

This early-phase trial tests whether adding a personalized immune treatment to standard chemotherapy can prevent cancer recurrence in colorectal cancer patients who have minimal residual disease (MRD) after surgery. Ten adults aged 18-80 with stage II (high-risk) or stage III col…

This study tests a low dose of the immunotherapy drug nivolumab, alone or with chemotherapy, in people with advanced colorectal or stomach cancers that have a specific genetic feature (MSI/dMMR). The goal is to see if this approach can shrink tumors before surgery or control the …

This phase 2 trial is testing whether low doses of the immunotherapy drugs nivolumab or pembrolizumab can shrink tumors in people with a specific genetic type of colorectal cancer (MSI/dMMR) before they have surgery. The study involves 30 participants with stage II-III disease wh…

This study looks at how well a combination of three drugs—capecitabine, oxaliplatin, and bevacizumab—works as a first treatment for elderly patients (70 and older) with metastatic colorectal cancer that cannot be removed by surgery. The goal is to see if this approach can delay c…

This early-phase study tests whether adding Akkermansia probiotics to standard immunotherapy and chemotherapy can safely help patients with advanced colorectal cancer that hasn't responded to prior treatments. The trial enrolls 22 adults whose tumors are MSS/pMMR type, which typi…

This study tests a new treatment approach for people with advanced colorectal cancer that has spread to the liver, lungs, or abdomen and cannot be removed with surgery. The treatment combines a short course of radiation with immunotherapy (tislelizumab), chemotherapy (CAPOX), and…

This was a phase 2 study planned to test a new drug called NGM707 combined with the immunotherapy pembrolizumab in people with advanced or metastatic solid tumors, specifically colorectal cancer. The goal was to see if the combination could shrink tumors and to check for side eff…

This phase II trial tests whether adding tocotrienol, a form of vitamin E, to standard chemotherapy and bevacizumab can improve treatment and reduce side effects in people with metastatic colorectal cancer. About 83 participants will be randomly assigned to receive either tocotri…

This early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…

This phase 2 trial is testing a combination of two drugs, cabozantinib and nivolumab, in 48 people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if the combination can shrink or stabilize tumors. All participants have a type of …

This study is observing 300 adults with metastatic colorectal cancer who are receiving a combination of two drugs (fluoropyrimidine and bevacizumab). The goal is to measure how long patients live and how long the cancer stays under control. The study is not testing a new treatmen…

This early-stage trial tests a personalized cell therapy for people with advanced colorectal, pancreatic, or lung cancers that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune T cells, engineering them to recognize and attack cancer cells, …

This study tests a new drug called E7386 combined with other cancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. About 300 …

This early-phase trial tests a new drug called HRO761, alone or combined with pembrolizumab or irinotecan, in people with advanced solid tumors that have high microsatellite instability (MSI-high) or mismatch repair deficiency (dMMR). The main goals are to check safety and find t…

This study tests a combination of three drugs—fruquintinib, an immunotherapy, and an oral chemo—in people with advanced colorectal cancer that has stopped responding to standard treatments. The goal is to see if this mix can shrink tumors and extend life. About 106 participants w…

This study tests whether giving chemotherapy before and after surgery (plus heated chemo directly into the abdomen) helps people with colorectal cancer that has spread to the lining of the abdomen live longer. About 358 adults with resectable disease are randomly assigned to eith…

This study compares two minimally invasive treatments—microwave ablation and stereotactic body radiation therapy—for colorectal cancer that has spread to the liver. About 100 patients with 1 to 3 liver tumors that cannot be surgically removed will be randomly assigned to one of t…

This study tests a new drug (JAB-21822) combined with cetuximab in people with advanced colorectal, small intestine, or appendiceal cancers that have a specific KRAS G12C mutation. Participants must have already tried at least one standard treatment. The goal is to see if the com…

This early-stage study tests the safety of tucatinib in about 25 Chinese patients with advanced HER2+ breast, stomach, or colorectal cancer that has worsened after standard treatments. Researchers will monitor side effects and how the drug moves through the body. The goal is to s…

This study tests whether low-dose aspirin can help prevent colorectal cancer from coming back in patients whose tumors have certain genetic changes (in the PI3K pathway). Over 600 patients who had surgery for stage II or III colon or rectal cancer are randomly assigned to take as…

This study planned to test two drugs, regorafenib and lorigerlimab, given before surgery to people with colorectal cancer that had spread only to their lungs. The goal was to see if the combination was safe and could help shrink tumors. However, the trial was withdrawn before any…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This study tests two immunotherapy drugs, AK119 and AK112, alone or with chemotherapy, in 170 people with a common type of colorectal cancer (pMMR/MSS). The goal is to see if these combinations shrink tumors and are safe. The trial is active but not recruiting new participants.

This early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.

This study looks at whether a 6-month exercise program (a mix of aerobic and resistance training) can improve fitness and reduce the risk of cancer coming back in patients who had surgery for colorectal cancer that spread to the liver. About 66 participants will be split into thr…

This Phase 2 trial tests a combination of three drugs—Tislelizumab, Fruquintinib, and Metronidazole—in 33 adults with advanced colorectal cancer that has not responded to earlier treatments. The goal is to see if this mix can slow cancer growth and improve survival. Participants …

This study compares two ways of preparing the bowel before left-sided colorectal cancer surgery: standard mechanical bowel prep alone versus mechanical prep plus oral antibiotics (rifaximin and metronidazole). The goal is to see if adding antibiotics reduces surgical site infecti…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This phase 3 trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy and bevacizumab helps people with a specific type of advanced colorectal cancer (RAS-mutant, MSS) live longer without their cancer growing. About 446 adults who have not had prior t…

This early-phase study tests an experimental drug called MCLA-129, a bispecific antibody that targets two cancer-related proteins (EGFR and c-MET). It is for people with advanced non-small cell lung cancer, gastric cancer, esophageal cancer, head and neck cancer, or colorectal ca…

This phase II study aimed to test two immunotherapy drugs (tiragolumab and atezolizumab) combined with targeted radiation in people with microsatellite stable (MSS) metastatic colorectal cancer, a type that typically doesn't respond to immunotherapy. The trial was withdrawn befor…

This pilot study aimed to see if adjusting the dose of the chemotherapy drug 5-FU based on its concentration in the blood could improve treatment for metastatic colorectal cancer. The study was withdrawn before enrolling any participants. It was designed for adults with metastati…

This study tests a new genetic vaccine called Nous-209, given together with the immunotherapy drug pembrolizumab (Keytruda), in adults with advanced MSI-H or dMMR solid tumors (colorectal, gastric, or gastro-esophageal junction cancers). The vaccine is designed to train the immun…

This study compares two treatments for colorectal cancer that has spread to the liver: surgical removal of tumors versus a less invasive needle ablation procedure guided by 3D imaging. 230 patients are randomly assigned to one of the two treatments. The goal is to see if ablation…

This early-phase trial is testing a new type of cell therapy called P-MUC1C-ALLO1 for people with advanced solid tumors (like breast, ovarian, lung, or pancreatic cancer) that have not responded to other treatments. The therapy uses donor immune cells engineered to recognize and …

This study aimed to see if adding the targeted drug inavolisib to standard chemotherapy and bevacizumab could help people with a specific genetic form of advanced colorectal cancer (PIK3CA-mutated). It was designed for adults who had not yet received treatment for metastatic dise…

This study tests an experimental drug called WTX-330 in 100 adults with advanced solid tumors or non-Hodgkin lymphoma that have not responded to standard treatments. The trial has two parts: first, finding the safest dose and schedule, then expanding to see how well the drug work…

This study compares two ways of giving chemotherapy directly into the belly after surgery to remove visible cancer from the lining of the abdomen. The cancer comes from the appendix, colon, or rectum. About 292 adults will be randomly assigned to receive either early post-operati…

This small pilot study is testing two immunotherapy drugs, botensilimab and balstilimab, in 16 people with advanced colorectal cancer that has not spread to the liver. Participants receive the drugs in 6-week cycles, and if the cancer progresses, standard chemotherapy is added. T…

This study tests whether using a blood test for circulating tumor DNA (ctDNA) can help doctors decide if patients with stage II or III colon cancer need stronger chemotherapy after surgery. The trial compares standard chemo with a more intense regimen (FOLFOXIRI) and an additiona…

This early-phase study tests an experimental oral drug (GSK4418959) in adults with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). The drug works by blocking a protein (WRN) that these tumors need to survive. The study aims to see if the drug, alone or w…

This study tests a new drug called HCB101 given together with other cancer treatments for people with advanced solid tumors that have not responded well to prior therapy. About 500 adults will take part to find the safest dose and see if the combination can shrink tumors. The goa…

This expanded access program offers fruquintinib, a targeted cancer drug, to adults with metastatic colorectal cancer that has worsened after all standard treatments. Participants take the drug as a capsule daily for three weeks, then one week off. The goal is to provide access u…

This Phase 3 trial tests whether adding anlotinib (a daily pill) to standard chemotherapy can help people with a certain type of advanced colorectal cancer live longer without the disease getting worse. About 748 participants with RAS/BRAF wild-type cancer that has spread will re…

This early-phase study tests a new drug, DKY709, alone or with another drug (PDR001) in people with advanced solid tumors like lung cancer, melanoma, and breast cancer. The main goal is to find a safe dose and check for side effects. About 98 adults whose cancer worsened after st…

This phase II trial tests how well chemoradiation (using fluorouracil, leucovorin, and oxaliplatin) works before surgery for stage II or III rectal cancer. The study looks at different time intervals between chemoradiation and surgery to see which timing leads to the best tumor s…

This study tests whether adding extra stitches around the surgical connection in laparoscopic low rectal cancer surgery can reduce the risk of dangerous leaks. About 300 adults with low rectal cancer will be assigned to either standard surgery or surgery with reinforced stitching…

This study tests a combination of an experimental immune booster (N-803) with standard checkpoint inhibitors in people with advanced solid tumors (like lung, bladder, or skin cancer) whose disease progressed after prior immunotherapy. The goal is to see if the combo can shrink tu…

This early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…

This study compares two chemotherapy treatments, FOLFOX-6 and CAPOX, in 248 adults aged 20-70 with metastatic colorectal cancer that has spread after surgery. The goal is to see which regimen better controls the disease and causes fewer side effects like liver problems or severe …

This early-phase trial tests a new drug called JAB-21822, which targets a specific genetic mutation (KRAS G12C), combined with standard chemotherapy and bevacizumab. The study includes 30 Chinese patients with advanced colorectal cancer that has not responded to first-line treatm…

This early-phase trial tests a new approach to treat advanced solid tumors by giving patients a large dose of their own immune cells that are specially selected to attack cancer. The cells are taken from the tumor, multiplied in the lab, and then infused back. Some patients also …

This early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…

This phase II trial is testing whether combining two drugs—niraparib and panitumumab—can help people with advanced colorectal cancer that has spread. The study includes 26 patients whose cancer has not responded to at least one prior treatment. The goal is to see if the combinati…

This phase 2 study tests a drug called AK104, which helps the immune system attack cancer cells, in people with specific types of stomach or colorectal cancer. Participants receive the drug before and after surgery to see if it can completely eliminate the tumor. The trial involv…

This early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, …

This phase 3 study tests whether a combination of trifluridine/tipiracil (a chemotherapy pill) and bevacizumab (a targeted therapy) works better than the current standard of capecitabine plus bevacizumab for people with metastatic colorectal cancer who are not healthy enough for …

This study tests a combined pump and catheter system that delivers chemotherapy directly to the liver in adults with colorectal cancer that has spread to the liver or with bile duct cancer. The main goal is to see if the device is safe. About 100 participants will have the pump i…

This study tests a new drug, ABBV-400, combined with standard treatments for people with advanced colorectal cancer that has spread and cannot be removed by surgery. About 280 adults who have already tried one prior treatment will receive different doses of ABBV-400 plus chemothe…

This phase 2 trial is testing the immunotherapy drug pembrolizumab (Keytruda) in 25 adults with a specific type of advanced colorectal cancer (dMMR) that cannot be surgically removed. The goal is to see if the drug can shrink the tumors enough to make surgery possible. Treatment …

This early-phase trial is testing a combination of two immunotherapy drugs, naptumomab estafenatox and durvalumab, in 120 people with advanced or metastatic solid tumors like pancreatic, ovarian, and lung cancer. The main goal is to find a safe dose and see how the body reacts. R…

This phase 3 trial tests whether combining regorafenib and irinotecan works better than regorafenib alone for people with metastatic colorectal cancer who have already tried standard treatments. About 377 participants will receive either the combo or the single drug. The main goa…

This study tests a new drug (HR070803) added to standard chemotherapy and a targeted therapy for people with advanced colorectal cancer that has spread and cannot be removed by surgery. About 669 participants will receive either the new combo or standard treatment. The goal is to…

This early-stage trial is testing a new drug called ELVN-002 in combination with trastuzumab and chemotherapy for people with advanced HER2-positive solid tumors, including breast, gastric, and colorectal cancers. The main goal is to find a safe dose and understand side effects. …

This study tests a combination of two drugs (vorbipiprant and balstilimab) in people with advanced colorectal or other gastrointestinal cancers that have not responded to prior treatments. The goal is to see if the combination is safe and can shrink tumors or slow disease progres…

This early-phase study tests an experimental drug called ABBV-400, alone or with another drug (bevacizumab), in about 520 adults with advanced solid tumors including lung, stomach, and colorectal cancers. The goal is to find the safest and most effective dose and see if it can sh…

This study was designed to test an experimental immunotherapy called AlloStim combined with a checkpoint inhibitor (avelumab) in people with advanced colorectal cancer that had stopped responding to multiple prior treatments. The trial was withdrawn before any participants were e…

This early-phase trial tests a new antibody drug called IMT-009, given alone or with the cancer pill fruquintinib, in about 67 people with advanced solid tumors or lymphomas that have stopped responding to standard treatments. The main goals are to find a safe dose, understand si…

This study tests two experimental drugs, AK112 and AK117, alone or together, in people with metastatic colorectal cancer that cannot be removed with surgery. The goal is to see if the drugs can shrink tumors or slow the disease. About 254 participants will be enrolled, and the st…

This phase 2 trial compares a new 'dose-dense' schedule of capecitabine (one week on, one week off) against the standard regimen (two weeks on, one week off) in 100 people with colorectal cancer. The main goal is to see if the new schedule improves quality of life. The study is a…

This early-phase trial tests a new drug called TORL-3-600 in 70 people with advanced solid tumors or colorectal cancer. The drug is an antibody drug conjugate designed to target and kill cancer cells. The main goals are to check safety, find the best dose, and see if it can shrin…

This was a planned Phase 2 trial to test the drug CBX-12 in people with advanced colorectal cancer that had stopped responding to standard treatments. The drug was designed to deliver a cancer-killing substance directly to tumor cells. However, the study was withdrawn before any …

This study tests a combination of three drugs (tiragolumab, atezolizumab, and bevacizumab) in people with a type of advanced colorectal cancer that has not responded to prior treatments. The goal is to see if the combo can shrink tumors or slow the disease. Participants receive t…

This phase 2 trial is testing a combination of four drugs—irinotecan, dabrafenib, trametinib, and either cetuximab or panitumumab—as a second-line treatment for people with metastatic colorectal cancer that has a BRAF V600E mutation. The study aims to see how well this drug mix s…

This phase 2 trial is testing whether adding a liver-directed chemoembolization procedure to standard chemotherapy can better shrink tumors in people with colorectal cancer that has spread only to the liver and has a poor outlook. About 48 participants will receive either chemoth…

This early-stage trial is testing a new drug called HBI-2438 in people with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have a specific genetic change called KRAS G12C. The main goals are to find the safest dose and understand how the drug moves throu…

This early-stage trial tests a new oral drug called HBI-2376 in about 42 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have KRAS or EGFR mutations and have stopped responding to standard treatments. The main goals are to find a safe dose and unde…

This study aimed to see if the immunotherapy drugs nivolumab and ipilimumab could help people with colorectal or gastroesophageal cancer avoid or delay major surgery. It was designed for adults with stage I to III cancers. However, the trial was withdrawn by the sponsor before en…

This study aimed to test whether a person's own immune cells, modified in a lab to target specific cancer-related mutations (KRAS or TP53), could prevent advanced gastrointestinal cancers from coming back after standard treatment. Participants would have been randomly assigned to…

This study tests whether improved nutritional support, delivered through digital tools and personalized advice, can reduce malnutrition in cancer patients. Around 130 adults with gynecologic, colorectal, or lymphoma cancers will receive either standard dietary advice or enhanced …

This study tests a new drug called nelmastobart combined with the chemotherapy capecitabine in people with metastatic colorectal cancer that no longer responds to standard treatments. About 59 adults will receive the combination to see if it is safe and can slow cancer growth. Th…

This phase 2 trial tests two experimental immunotherapy drugs, botensilimab and balstilimab, alone or together, against standard chemotherapy in 234 people with metastatic colorectal cancer that has not responded to prior treatments. The goal is to see if these drugs can shrink t…

This study aimed to test a combination of two drugs—LY3200882 and capecitabine—in people with advanced colorectal cancer that had stopped responding to chemotherapy. The goal was to see if the combination could re-sensitize tumors to treatment. However, the trial was withdrawn be…

This study was designed to test a combination of two drugs, Ezabenlimab and BI907828, in people with advanced solid tumors like sarcoma, lung cancer, and breast cancer. The goal was to see if the treatment could control the disease for at least 24 weeks. However, the trial was wi…

This study tests a new oral drug called XS-03 combined with standard chemotherapy and a targeted antibody (bevacizumab) in 102 people with metastatic colorectal cancer that has a RAS mutation. The goal is to see if the combination is safe and shrinks tumors better than current tr…

Researchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…

This study tests a new platform called xDRIVE that combines drug sensitivity testing and AI to predict which treatments will work best for people with advanced colorectal cancer. The platform will not provide treatment itself but will give doctors a recommendation. The goal is to…

This early-phase study tests how well a special PET-CT scan called FAZA can measure oxygen levels in solid tumors like breast, colorectal, and pancreatic cancers. About 25 participants will receive the FAZA tracer and undergo imaging to see if the results are consistent over time…

This study is developing a blood test that looks for specific DNA changes to find colorectal cancer early, even before symptoms appear. Researchers are analyzing blood samples from 500 people with and without cancer to see how accurate the test is. The goal is to create a simple,…

This early-phase trial tests a radioactive imaging agent called Technetium-99m HYNIC-FAPI in 15 people with metastatic lung, pancreas, breast, or colorectal cancer. The goal is to see how well it highlights tumors on SPECT/CT scans. Researchers will measure where the agent goes i…

This study is testing a new imaging agent called 18F-FSPG to see if it can better detect liver cancer (hepatocellular carcinoma) and other liver tumors compared to standard PET scans. About 110 adults with liver cancer or benign liver tumors will receive the tracer before their s…

This study is testing a new blood test called LUNAR-2 that looks for DNA from colorectal cancer in the bloodstream. It involves over 44,000 average-risk adults aged 45-84 who are already scheduled for a screening colonoscopy. The goal is to see how well this blood test can detect…

This study tests whether combining spectral CT scans with a genetic test (MSI) can more accurately predict if colorectal cancer has spread to nearby lymph nodes. Researchers will compare the imaging results with actual tissue samples from surgery or biopsy. The goal is to improve…

This study looks at whether stool-based tests (like the FIT test and Cologuard) can accurately detect colorectal cancer and precancerous polyps in adults with cystic fibrosis. Researchers will compare these non-invasive tests to the standard colonoscopy in 350 participants. The g…

This study tests whether sending a colorectal cancer screening test directly to people's homes, without needing to order it first, increases the number of people who get screened. It involves 64,000 adults aged 50-74 in France. The goal is to see if this simple change leads to mo…

This study tests a computer program that analyzes colonoscopy images to help doctors decide if a growth (polyp) is an adenoma (pre-cancerous) or not. The software gives a probability score for each lesion. The trial involves 1,178 adults and compares the software's results to lab…

This study looks at whether a blood test that detects tumor DNA can help decide which people with diverticulitis need a colonoscopy to check for colorectal cancer. Currently, almost everyone with diverticulitis is advised to get a colonoscopy, but many are unnecessary. The resear…

This study looks at whether CT scans can be used instead of colonoscopies to screen for colon cancer. Researchers will compare how well each method finds polyps and cancer in 600 adults aged 50-70. If CT scans work just as well, it could offer a faster and less invasive screening…

This study looks at whether a blood test can detect if cancer comes back after surgery for colorectal or appendix cancer that spread to the abdomen. Researchers will collect blood samples from 55 patients before and after surgery to measure DNA changes. The goal is to see if this…

This study aims to see how well a new stool test, called LifeKit Prevent, can detect colorectal cancer and precancerous growths (adenomas). About 12,000 adults aged 40 and older scheduled for a screening colonoscopy will provide a stool sample for the test. The results will be co…

This study was designed to see how often the Metabiomics stool test fails to detect colon cancer in people already diagnosed and awaiting surgery. No one was enrolled because the study was withdrawn. The goal was to measure the test's false negative rate.

This study compares two mailed stool tests—Cologuard and FIT—for colorectal cancer screening in adults aged 45-49 who are not up to date with screening. Researchers will measure how many people complete screening and follow up on abnormal results. The goal is to find the most eff…

Researchers are testing an experimental vaccine called Ad5.F35-hGCC-PADRE in adults who have had surgery and standard treatment for gastrointestinal cancers, including pancreatic, colorectal, esophageal, gastric, and small bowel adenocarcinomas. The trial aims to find a safe dose…

This large study compares two common colorectal cancer screening methods: colonoscopy and annual fecal immunochemical testing (FIT). Over 50,000 veterans aged 50-75 will be randomly assigned to one of the two screenings and followed for 10 years. The goal is to see which approach…

This trial tests whether an annual stool-based test (FIT) can be as effective as routine colonoscopy for people who have had advanced polyps removed. Participants aged 50 to 65 from colorectal cancer screening programs will be randomly assigned to either yearly FIT or scheduled e…

This study tests whether a high-fiber diet centered on legumes like dry beans can help overweight or obese adults who have had colon polyps lose weight and reduce their risk of colon cancer. Participants follow a diet with pre-portioned meals for up to a year, with nutritionist s…

This study looks at whether taking aspirin in different patterns can help prevent colorectal cancer in people who have had colon polyps (adenomas). Aspirin may block certain enzymes that help cancer cells grow. The trial enrolled 81 adults with a history of colon polyps and measu…

This study tests whether sending text reminders to patients who are overdue for colorectal cancer screening helps them follow through and get a colonoscopy or stool test. About 3,888 adults with a scheduled primary care visit will take part. The goal is to make it easier for peop…

This study compares time-restricted eating (eating only between 12pm-8pm) to daily calorie restriction for weight loss and colorectal cancer risk reduction in 193 obese adults aged 45-70. Participants follow their assigned diet for 6 months, then a maintenance phase for another 6…

This study tests three different eating plans to see which helps overweight adults at risk for colorectal cancer eat healthier and lose weight. About 240 participants will follow one of the plans for 12 months, with support from phone calls and a phone app. The goal is to find be…

This study looks at whether taking low-dose aspirin can lower the risk of colorectal cancer in people who have already had precancerous polyps removed. Researchers measure changes in certain stem cell markers in the colon and other substances in the blood and urine. The goal is t…

This phase IIb trial tests whether a vaccine called Tri-Ad5, combined with an immune booster N-803, can prevent colon cancer in people with Lynch syndrome. The vaccine targets proteins found in precancer and cancer cells, aiming to train the immune system to destroy them. 186 par…

This phase II trial tests whether riluzole, a drug used for ALS, can prevent nerve damage caused by oxaliplatin chemotherapy in people with stage II/III colorectal cancer. About 80 participants will receive either riluzole or a placebo during their chemo. The study is currently s…

This study tests whether a mobile health tool called mPATH™-Cloud can help more people get screened for colorectal cancer. Over 1,000 patients from a community health center in North Carolina who are overdue for screening will either receive usual care or get a link to the tool, …

This large pilot study in Norway is comparing two common colorectal cancer screening methods—flexible sigmoidoscopy (a one-time scope exam) and biennial fecal immunochemical testing (a stool test)—to see which works best for the general population. Over 140,000 men and women aged…

This large study is testing whether a screening procedure called flexible sigmoidoscopy can lower the number of colorectal cancer cases and deaths. About 100,000 men and women aged 50-64 in Norway are taking part. The study also looks at adding a stool blood test and how screenin…

This study tests whether adding canned navy beans to your daily diet can improve gut bacteria and lower obesity-related cancer risk. About 71 adults who are overweight and have a history of colorectal polyps or cancer will eat beans for 8 weeks. Researchers will check changes in …

This study tests whether taking two drugs, eflornithine and sulindac, together can lower the chance of new high-risk growths or a second colon cancer in people who have already had stage 0 to III colon or rectal cancer. About 350 participants who are cancer-free after surgery wil…

This study tests ways to help more people complete a colonoscopy after an abnormal stool-based colorectal cancer screening test. The researchers will use team-based best practices in clinics and a patient app with enhanced instructions and navigation. About 2,000 adults who speak…

This phase II/III trial tests whether duloxetine, a drug used for depression and pain, can prevent the nerve damage (pain, tingling, numbness) caused by oxaliplatin chemotherapy in stage II-III colorectal cancer patients. About 220 participants will receive either duloxetine or a…

This study tests whether atorvastatin, a widely used cholesterol medication, can reduce the risk of colon cancer in people with long-standing ulcerative colitis who carry a specific genetic mutation (P53). About 42 participants will take either atorvastatin or a placebo for a per…

This study tests whether personalized screening can prevent stomach and colon cancer in 40,000 healthy adults aged 50-75. For stomach cancer, researchers combine a test for H. pylori bacteria with a blood test for stomach damage to identify high-risk individuals. For colon cancer…

This study tests a program called CARES-REACH that trains healthcare providers and uses electronic medical record tools to increase colorectal cancer screening rates in rural clinics. Researchers are working with 49 staff and providers from two healthcare systems. The goal is to …

This study tests whether sending a letter, a home stool test kit (FIT), and follow-up phone calls can increase colorectal cancer screening among 3,000 patients aged 45-75 at community health centers in Brooklyn. Those who respond get help completing the test or scheduling a colon…

This study looked at whether taking a daily aspirin can reduce the risk of colorectal cancer in people who have already had a precancerous polyp (adenoma) removed. Researchers measured certain substances in urine and blood that are linked to inflammation and cancer growth. The go…

This study uses artificial intelligence to find people aged 45-49 who are at higher risk for colorectal cancer but have never been screened. Participants are randomly assigned to receive either standard care or extra help from a patient navigator who guides them through getting a…

This pilot study offers free legal services to caregivers and patients dealing with advanced colorectal cancer. The goal is to see if early legal support can reduce financial and emotional stress. Twenty patient-caregiver pairs will receive personalized legal help from a nonprofi…

Researchers test an 8-week online precision nursing education program for young colorectal cancer survivors. The program includes Qigong exercise and mindfulness training delivered through an e-flipped classroom model. The study measures changes in depression symptoms and mindful…

This Phase 3 trial tests a drug called M701, given as an injection into the belly, to see if it can reduce the need for draining fluid in people with malignant ascites from advanced stomach, colorectal, or ovarian cancer. About 312 participants will either receive M701 plus drain…

This trial asks whether an opioid-free anesthesia method can control acute pain after laparoscopic colorectal surgery as well as or better than standard opioid-based anesthesia. Adults aged 18 to 90 scheduled for this surgery will be randomly assigned to receive either a combinat…

This study tests whether a personalized exercise program, guided by video-based movement analysis, can help people with chemotherapy-induced peripheral neuropathy (CIPN) — a common side effect causing numbness, tingling, and balance problems. The trial enrolls adults with breast,…

This phase 2 study tests whether acupuncture can improve memory, focus, and thinking problems (often called 'chemo brain') in people who have had breast, colorectal, prostate, or gynecological cancer. About 48 participants will receive either real acupuncture or sham (fake) acupu…

This study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …

This study tests whether a tailored exercise program and nutritional guidance can reduce peripheral neuropathy (nerve damage) and fatigue in people with colorectal cancer receiving chemotherapy. Participants follow a supervised exercise routine and monthly nutrition check-ins dur…

This pilot study investigates whether a liquid food product made from fermented mushroom extracts (AndoSanTM) can reduce fatigue in people who have had colorectal cancer. Participants with persistent moderate-to-severe fatigue will take the supplement for six weeks. Researchers w…

This trial tests whether removing the urinary catheter immediately after colorectal cancer surgery (before anesthesia wears off) is as safe and effective as removing it the next day. The goal is to lower the risk of urinary tract infections and help patients recover faster. About…

This trial tests whether watching an educational video before a surgical consultation helps colorectal cancer patients feel less anxious and more informed. About 100 adults scheduled for curative-intent colon or rectal surgery will be randomly assigned to either watch the video b…

This study aimed to compare personalized nursing care (including counseling, temperature monitoring, and recovery guidance) with standard nursing for people having laparoscopic colorectal cancer surgery. The goal was to see if the personalized approach could reduce anxiety, preve…

This study tests whether a therapy program that combines in-person sessions with a smartphone app can help cancer patients feel more flexible in dealing with difficult thoughts and emotions. About 120 adults with breast, lung, or colorectal cancer will be randomly assigned to one…

This study tests whether online group counseling can help people who have a permanent colostomy due to colorectal cancer adjust better and improve their psychological well-being and resilience. About 48 adults will be randomly assigned to receive the counseling or not. The goal i…

This study tests whether a personalized care plan, based on a geriatric assessment, can reduce severe side effects in older adults (65+) starting chemotherapy for common cancers. Participants are randomly assigned to receive the assessment-driven plan plus usual care, or usual ca…

This study tests whether talking to an exercise specialist over the phone can help breast and colorectal cancer survivors become more active. Many people become less active after cancer treatment, and this program aims to change that. The trial includes 120 participants who recen…

This phase III trial is testing whether a telehealth self-management program can improve care coordination and quality of life for survivors of non-small cell lung cancer or colorectal cancer. About 403 participants who finished treatment 4 months ago will receive coaching sessio…

This study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…

This study looks at whether a 16-week home exercise program can help Black and Hispanic patients with breast, colorectal, or prostate cancer become more active during chemotherapy. Participants will do aerobic and resistance exercises either with virtual supervision or on their o…

This study tests whether a personalized home exercise program can improve physical function and quality of life in people aged 75 and older with colorectal cancer who are having surgery. Participants receive weekly phone coaching on strength, balance, and breathing exercises from…

This study tests whether a live, personalized exercise and meditation coaching program, delivered through a digital app, can improve the quality of life for cancer survivors. The trial involves 146 adults who have had breast, lung, prostate, colorectal, or other cancers. Particip…

This study looks at whether giving morphine into the spine (intrathecal) before laparoscopic colon cancer surgery helps patients feel better and recover faster. About 252 adults having this surgery will be invited to join. The goal is to see if this approach reduces pain, cuts do…

This study tests whether an extra meeting with a team of doctors, a palliative care specialist, and a psychologist can help patients with advanced cancer feel less torn about their next treatment. 62 adults with metastatic lung, breast, colon, ovarian, or prostate cancer who need…

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

Researchers are building a large bank of blood and stool samples from people with advanced lung, breast, colorectal, and pancreatic cancers, plus healthy volunteers. The goal is to learn whether the mix of bacteria in a person's gut can predict how well cancer treatment works and…

This study looks at how Western habits—like drinking alcohol and eating late—might raise the risk of colorectal cancer. Twelve adults who have had colon polyps in the past will try four different weekly routines, including eating at normal times or late, with or without alcohol. …

This study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…

This study tests an expanded web-based decision aid for people with cholangiocarcinoma, colorectal cancer, or multiple myeloma. Participants use the tool to choose which genomic results—such as cancer biomarkers or inherited risks—they want to receive. The goal is to see if the t…

This study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…

This study watches how force feedback instruments work during robot-assisted surgeries with the da Vinci 5 system. About 200 adults having hernia, colorectal, thoracic, gynecologic, or partial kidney removal surgery will take part. The goal is to see how these tools help surgeons…

This pilot study is testing whether a simple blood test can detect tiny amounts of tumor DNA (ctDNA) in patients with early-stage colorectal cancer before and after surgery. The goal is to see if this test is practical and reliable for spotting any cancer cells left behind, which…

This study collects blood, tissue, and stool samples from 160 people aged 18-49, including those with young onset colorectal cancer and healthy volunteers. Researchers will analyze the samples to create a database that helps explain why colorectal cancer is rising in younger adul…

This study is testing whether a ketone supplement called beta-hydroxybutyrate (BHB) is safe and tolerable for people scheduled for a colonoscopy or flexible sigmoidoscopy as part of their standard care. Participants will take a drink containing R-1,3-butanediol three times daily …

This study tests two different drug combinations in people with advanced colorectal, pancreatic, or leiomyosarcoma cancers that have not responded to standard treatments. Participants receive either olaparib plus durvalumab or cediranib plus durvalumab. The main goal is to unders…

This study follows people with colorectal cancer that has spread to the lining of the abdomen (peritoneal metastasis) or with pseudomyxoma peritonei, a rare tumor of the abdominal cavity. Participants undergo cytoreductive surgery to remove all visible tumors, followed by intrape…

This study compares two strategies to increase colon and liver cancer screening among 30,300 veterans. One approach directly reaches out to veterans to schedule tests, while the other helps healthcare providers fix system issues. Researchers will track screening rates over 12 mon…

This study is testing whether regular blood tests that look for tumor DNA (called liquid biopsy) can help doctors make better treatment decisions for people with advanced colorectal or lung cancer. About 332 participants will be randomly assigned to either receive standard imagin…

This study tested whether routine screening for four cancers (prostate, lung, colorectal, and ovarian) can lower the number of people who die from these diseases. Over 154,000 adults aged 55–74 joined the trial. Researchers compared cancer deaths between those who got screened an…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can help doctors choose the right amount of chemotherapy for people with stage III colorectal cancer. About 2,450 participants will be split into groups based on their ctDNA results: those with negative c…

This study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…

This registry tracks adults with metastatic colorectal cancer who are starting their first systemic therapy. Researchers will collect information on the treatments doctors choose, how well they work, and patients' quality of life. The goal is to understand what happens in everyda…

This study looks at how common muscle loss (sarcopenia) is in people with gastrointestinal cancer. Researchers will use a short questionnaire to screen patients before and during treatment. Those flagged as at risk will get extra nutritional support. The goal is to see if early d…

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This study tests whether offering a blood test (cell free DNA) alongside standard stool tests and colonoscopy increases colorectal cancer screening rates among people who are not up-to-date with screening. The trial enrolls 340 adults aged 45-75 at a health center serving low-inc…

This long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…

This study tests new ways to help rural primary care clinics provide better follow-up care for cancer survivors. Researchers will give clinics telementoring, quality improvement coaching, and an obesity management toolkit. The goal is to see if these tools help clinics follow nat…

This study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…

This study looks at whether a special home care program helps people with a new stoma (a surgical opening on the belly) recover better after colorectal cancer surgery. About 98 adults who had a stoma created will get extra support and teaching to manage their stoma at home. The g…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study examines if the amount of a bacteria called Fusobacterium nucleatum in colon cancer tumors is linked to how well patients respond to targeted therapies like cetuximab or panitumumab. Researchers will analyze stored tumor samples from 500 patients with metastatic colore…

This study looks at how colorectal cancer affects the physical and emotional well-being of adolescents and young adults (ages 18-39). Researchers will measure symptoms like fatigue, pain, and anxiety, as well as physical fitness, to better understand the challenges these patients…

This study looks at whether telling people over 45 their genetic risk for colorectal cancer helps them decide to get their first colonoscopy. Researchers will track how many people schedule a colonoscopy after learning their risk, and compare findings like polyps between risk gro…

This study tests a new way of organizing care for people aged 70 and older who have cancer (breast, lung, colorectal, or prostate) plus at least one other serious health condition. The GERONTE program brings all their doctors and nurses together using a shared digital care plan. …

This study tests a special camera that measures oxygen levels in the bowel during colorectal surgery. Surgeons will use it to see if low oxygen areas predict leaks after the procedure. About 52 adults having laparoscopic colorectal surgery will take part. The goal is to see if th…

This study is testing whether people with cancer or diabetes can use a Fitbit and a continuous glucose monitor (CGM) to track their daily exercise and glucose levels. The goal is to see if it's practical and if people will stick with it. Thirty-five participants will wear both de…

This study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study looks back at the experiences of 37 people with colorectal cancer treated at a single hospital. Researchers are tracking how long patients survive after diagnosis. No new treatments are being tested; the goal is to learn from real-world outcomes.

This study aims to increase colorectal cancer screening among African Americans aged 45-72 who get care at community health centers in Michigan. Participants will learn about screening options (colonoscopy, stool tests) and choose one. Then they are randomly assigned to receive u…

This study looks at whether a simple blood test can find tiny bits of cancer DNA left in the body after surgery for colorectal cancer. The goal is to identify patients at high risk of the cancer coming back, so doctors can adjust follow-up care. Over 3,000 people with stage I-III…

This study looks at how well a stoma works and how it affects quality of life in people with colorectal cancer. Researchers will compare those who had a stoma created as an emergency procedure with those who had it planned ahead of time. About 700 participants will answer a quest…

This study looks at whether a blood test that detects tumor DNA can accurately identify patients who still have cancer after local removal of early-stage colorectal cancer. Currently, many patients undergo additional surgery even though about 85% are already cured by the initial …

This study enrolls 4,000 people with breast, ovarian, or colorectal cancer to test a comprehensive genetic panel. The panel looks for inherited cancer risks and tumor mutations that may affect drug sensitivity. Researchers aim to validate these genetic findings to potentially gui…

This study tests whether a simple blood test that looks for tumor DNA can detect colorectal cancer coming back earlier than standard CT scans. About 359 people who had surgery for stage II or III colorectal cancer will be randomly assigned to either the blood test plus frequent P…

This study looks at genetic and molecular markers in tissue and stool samples from people with colon cancer, colon polyps, and healthy controls. Researchers aim to understand how these markers differ and how they relate to cancer development. The study involves 582 participants a…

This study looks at how small changes in CT scan settings affect measurements of colorectal cancer tumors that have spread to the liver. About 169 adults with these tumors will get an extra CT scan. The goal is to see if tumor measurements stay reliable even when scan details var…

This study compares two surgical methods for emergency colon removal: laparoscopic (keyhole) and open surgery. Researchers want to see which approach leads to fewer complications and better long-term survival. The trial involves 192 adults who need emergency colon surgery, exclud…

This study was designed to test whether a special fluorescent dye and advanced cameras could help surgeons see colorectal cancer cells more clearly during operations. The goal was to remove all cancer cells and reduce the chance of the cancer coming back. However, the study was w…

This study looks at whether a quick, 8-item screening tool called G8 can help predict survival and severe side effects from treatment in elderly patients (70 years and older) with metastatic colorectal cancer. The goal is to find a simple way to identify which older patients are …

This study investigates genetic factors that may increase the risk of developing colorectal cancer at a young age (18-50). Researchers will collect blood or saliva samples and review medical records from 818 participants, including patients and their family members. The goal is t…

This study looks at how to improve colorectal cancer screening in rural clinics in Indiana. Clinics will mail FIT kits, send reminders, and use patient navigators to help people aged 45-75 get screened. The goal is to see which strategies work best to increase screening rates and…

This study analyzes tumor genes from 757 patients with advanced colorectal cancer to find markers that predict how well they respond to two different chemotherapy combinations. Participants receive either mFOLFOX6 plus bevacizumab or mFOLFOX6 plus panitumumab. The goal is not to …

This study looks at whether helping people aged 40-49 with a family history of colon cancer make informed choices about screening leads to more colonoscopies. Participants either get standard care (direct referral for colonoscopy) or a shared decision-making session where they ca…

This study looks at whether a detailed blood test can help doctors see how well treatment is working and predict if cancer will come back in people with colorectal cancer that has spread to the liver or lungs (up to 5 spots). The test checks for tumor DNA, RNA, proteins, and othe…

This pilot study is looking at whether dental erosion (loss of tooth enamel) could be a non-invasive biomarker for esophagogastric cancer and other cancers. Researchers will survey 174 participants (cancer patients and healthy volunteers) about diet, habits, and GERD symptoms, an…

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study looks at people aged 45-74 who had a positive fecal immunochemical test (FIT) but a normal colonoscopy. Even with a clear colonoscopy, these individuals may still have a higher risk of colorectal cancer. The trial will compare two follow-up options after two years: ano…

This study is a national registry collecting data from 1500 people with familial adenomatous polyposis (FAP) and related conditions across 28 Italian centers. It aims to better understand how these diseases progress, how they are currently managed, and what factors influence outc…

This observational study looks back at 700 patients from 15 hospitals in 2 countries to compare local treatments like surgery and radiation for brain metastases that spread from colorectal cancer. Researchers will track how long patients live and how long it takes for brain tumor…

This study aimed to see if giving patients a simple pamphlet with a social norm message (showing how their clinic's screening rate compares to others) could increase the number of people completing a take-home colorectal cancer screening test (FIT). The plan was to enroll adults …

This study looks at how the drug tucatinib enters and works in HER2+ cancers that have spread to the brain. Nine adults with breast, lung, or other cancers will take tucatinib before brain surgery. Researchers will test tumor samples to find genetic clues about why some cancers s…

This trial tests a dye mixture called Luminomark, which is injected into the colon wall near a tumor during a colonoscopy. The dye glows under a special camera during surgery, helping surgeons see exactly where to cut. The study involves 30 adults with early-stage colorectal canc…

This study follows over 96,000 Seventh-day Adventists in the U.S. and Canada to see how diet and lifestyle choices relate to breast, colorectal, and prostate cancer. Researchers are focusing on intakes of meat, soy, and dairy. Because it is observational, it can show patterns but…

This study is collecting blood samples from 102 patients with non-small cell lung cancer, colorectal cancer, or pancreatic cancer who are receiving standard treatments. Researchers will analyze the blood for cancer DNA (ctDNA) to see how it changes over time and whether it relate…

This study aimed to find out if certain genes that affect bleeding can cause a false positive result on a stool test used to screen for colon cancer. Researchers planned to compare genetic markers in people who had a high test result but a normal colonoscopy with those who had no…

This study is testing a blood test that looks for tiny bits of cancer DNA in the blood after colorectal cancer surgery. The goal is to see if this test can predict whether the cancer will return. Over 1,000 people with stage II or III colorectal cancer will be followed for up to …

This study looks at gene changes in tumor tissue from 787 people with advanced or recurrent colorectal cancer who took part in an earlier treatment study. Researchers want to see if certain genes are linked to how long patients lived or how long their cancer stayed under control.…

This study aimed to see if changing how cancer patients think about their illness could improve their quality of life and treatment outcomes. Researchers planned to follow newly diagnosed patients and give some a short mindset training. However, the study was withdrawn before any…

This study looks at two new models of follow-up care for people who have finished treatment for early-stage breast or colorectal cancer. The goal is to see if these models help survivors get the recommended cancer surveillance and preventive care. About 2450 adults from Kaiser Pe…

This study tests whether giving doctors real-time feedback from an AI program during colonoscopy helps them find more polyps (adenomas). Over 4,000 participants will have their colonoscopy monitored, and the AI will highlight suspicious areas on the screen. The goal is to see if …

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can help monitor for cancer recurrence in people with stage III colorectal cancer. Researchers will follow 137 participants over time to see if ctDNA levels relate to survival and whether they are better …

This study searches for new gene changes (mutations) that appear in cancer patients but not in their healthy parents. By comparing DNA from 1,275 people with certain cancers and their families, researchers hope to find genetic clues that increase cancer risk. The goal is to bette…

This study looks at 100 adults with colon obstruction caused by cancer. It compares emergency surgery with a stent (a tube to open the blockage) to see which leads to better recovery and long-term survival. The goal is to find the best approach for this urgent condition.

This study looks at whether a blood test (liquid biopsy) can find cancer mutations as well as the standard tissue biopsy. Researchers will compare the two methods in 1,500 advanced cancer patients to see if the blood test helps doctors choose better treatments and saves money. Th…

This study looks at how moderate aerobic exercise (like brisk walking) might help prevent colorectal cancer from coming back. Researchers will measure changes in inflammation and other blood markers in 60 people who have finished cancer treatment. Participants either walk on a tr…

The IMPACT Study is testing two online tools—GeneSHARE and LivingLabReport—to help people with inherited cancer gene variants share their results with family members and follow cancer screening guidelines. The study involves 720 adults who have a genetic variant linked to cancers…

This study looks back at data from 128,000 colorectal cancer patients in Germany to compare robot-assisted surgery with standard laparoscopic surgery. The goal is to see if robot-assisted surgery leads to fewer conversions to open surgery, fewer complications, and better long-ter…

This study tests whether sending patients direct reminders and giving their doctors electronic nudges can increase colorectal cancer screening rates. About 20,000 adults aged 50-72 who are overdue for screening will be randomly assigned to receive different types of outreach or u…

This study follows 637 people with a specific type of colorectal cancer called microsatellite instability (MSI). The goal is to identify factors that predict how the cancer will behave and whether chemotherapy helps. By collecting clinical and molecular data, researchers hope to …